Atossa Therapeutics/$ATOS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
- Ticker
- $ATOS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- Seattle, United States
- Website
- www.atossatherapeutics.com
ATOS Metrics
BasicAdvanced
$20M
-
-$3.84
-
-
Price and volume
Market cap
$20M
52-week high
$7.56
52-week low
$1.70
Average daily volume
82K
Financial strength
Current ratio
5.347
Quick ratio
4.369
Profitability
EBITDA (TTM)
-35.883
Management effectiveness
Return on assets (TTM)
-53.13%
Return on equity (TTM)
-96.90%
Valuation
Price to book
0.93
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
-0.519
Free cash flow yield (TTM)
-192.55%
Free cash flow per share (TTM)
-3.909
Growth
Earnings per share change (TTM)
9.08%
3-year earnings per share growth (CAGR)
2.74%
10-year earnings per share growth (CAGR)
-39.75%
What the Analysts think about ATOS
Analyst ratings (Buy, Hold, Sell) for Atossa Therapeutics stock.
Analyst projections of the future price of Atossa Therapeutics stock.
ATOS Financial Performance
Revenues and expenses
ATOS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.